11.01.23
After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an updated analysis of the ongoing real-world CLARENCE study in England were presented at the 9th Joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS). Mavenclad is a DMT that has been available in England since 2017 as a treatment for highly active relapsing MS.
Beginning in 2017, longitudinal data were anonymously collected for 2685 patients who were prescribed Mavenclad in England using the National Health System Blueteq high-cost drug database. Expanded disability status scale (EDSS) score and treatment history were recorded at treatment initiation, showing that 36.1% (n=969) of participants were treatment naïve, and the median EDSS score of the population was 2. Change in EDSS score, treatment switching, and persistence were evaluated for 5 years of follow-up until 2022, with the following observations recorded through descriptive analysis of longitudinal data:
There were 959 participants who had evaluable EDSS scores from both years of treatment with Mavenclad, and of them, 818 (85.3%) showed no change or a decrease in score, demonstrating high rates of stable disability. Overall, the findings from 5 years of follow-up from the CLARENCE study suggest that Mavenclad is effective in a real-world setting as a treatment for highly active RMS.
This study was sponsored by Merck, with authors from the Queen Scare MS Centre of the University College London and Merck Serono, Ltd.
Bénédicte Dansereau, MD, and Leo H. Wang, MD, PhD
Nicholas J. Silvestri, MD
Abdalmalik Bin Khunayfir, MD, and Brian Appleby, MD
